Vesigen Therapeutics

Vesigen Therapeutics

Biotechnology, 790 Memorial Dr, Cambridge, Massachusetts, 02139, United States, 11-50 Employees

vesigentx.com

  • twitter
  • LinkedIn

phone no Phone Number: 16*********

Who is VESIGEN THERAPEUTICS

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called...

Read More

map
  • 790 Memorial Dr, Cambridge, Massachusetts, 02139, United States Headquarters: 790 Memorial Dr, Cambridge, Massachusetts, 02139, United States
  • 2019 Date Founded: 2019
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from VESIGEN THERAPEUTICS

Vesigen Therapeutics Org Chart and Mapping

Employees

Adam Francoeur

Downstream Process Development Associate

Komal Vyas

Research Associate I

Gary Hao

Vice President, Cmc

Lorien Moore

VP, Corporate Development, Business Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Vesigen Therapeutics

Answer: Vesigen Therapeutics's headquarters are located at 790 Memorial Dr, Cambridge, Massachusetts, 02139, United States

Answer: Vesigen Therapeutics's phone number is 16*********

Answer: Vesigen Therapeutics's official website is https://vesigentx.com

Answer: Vesigen Therapeutics's revenue is $5 Million to $10 Million

Answer: Vesigen Therapeutics's SIC: 2836

Answer: Vesigen Therapeutics's NAICS: 541714

Answer: Vesigen Therapeutics has 11-50 employees

Answer: Vesigen Therapeutics is in Biotechnology

Answer: Vesigen Therapeutics contact info: Phone number: 16********* Website: https://vesigentx.com

Answer: Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access